Literature DB >> 24728517

Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

Mathilde Feist1, Xiaohua Huang, Joachim M Müller, Beate Rau, Wolfgang Dubiel.   

Abstract

PURPOSE: A frequently used chemotherapeutic agent in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitomycin C (MMC) which induces DNA damage and apoptosis in tumor cells. In addition, MMC activates DNA damage response (DDR) leading to repair mechanisms counteracting the effect of chemotherapy. COP9 signalosome (CSN) positively influences the DDR pathway by its intrinsic deneddylating and associated kinase activities. In an in vitro HIPEC model, we studied the impact of curcumin, an inhibitor of CSN-associated kinases, and of the microRNA (miRNA) let-7a-1, an inhibitor of CSN subunit expression, on the MMC-induced apoptosis in human HT29 colon cancer cells.
METHODS: Cells were incubated at 37 °C and indicated concentrations of MMC in a medium preheated to 42 °C as under HIPEC conditions for 1 or 4 h. HT29 cells were cotreated with 50 μM curcumin or transfected with let-7a-1 miRNA mimic. After incubation, cells were analyzed by Western blotting, densitometry, and caspase-3 ELISA.
RESULTS: An increase of CSN subunits in response to MMC treatment was detected. Apoptosis was only measured after 4 h with 50 μM MMC. MMC-induced apoptosis was elevated by cotreatment with curcumin. Transfection of HT29 cells with let-7a-1 reduced the expression of tested CSN subunits associated with the accumulation of the pro-apoptotic factors p27 and p53.
CONCLUSIONS: In response to MMC treatment, the CSN is elevated as a regulator of DDR retarding apoptosis in tumor cells. The therapeutic effect of HIPEC can be increased by inhibiting CSN-associated kinases via curcumin or by blocking CSN expression with let-7a-1 miRNA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24728517     DOI: 10.1007/s00384-014-1861-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  45 in total

1.  The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation.

Authors:  Eric S Fischer; Andrea Scrima; Kerstin Böhm; Syota Matsumoto; Gondichatnahalli M Lingaraju; Mahamadou Faty; Takeshi Yasuda; Simone Cavadini; Mitsuo Wakasugi; Fumio Hanaoka; Shigenori Iwai; Heinz Gut; Kaoru Sugasawa; Nicolas H Thomä
Journal:  Cell       Date:  2011-11-23       Impact factor: 41.582

Review 2.  Function and regulation of cullin-RING ubiquitin ligases.

Authors:  Matthew D Petroski; Raymond J Deshaies
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

3.  A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits.

Authors:  M Seeger; R Kraft; K Ferrell; D Bech-Otschir; R Dumdey; R Schade; C Gordon; M Naumann; W Dubiel
Journal:  FASEB J       Date:  1998-04       Impact factor: 5.191

Review 4.  The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity.

Authors:  M Tomasz; Y Palom
Journal:  Pharmacol Ther       Date:  1997 Oct-Dec       Impact factor: 12.310

5.  Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia.

Authors:  Joerg O W Pelz; Malte Vetterlein; Tanja Grimmig; Alexander G Kerscher; Eva Moll; Maria Lazariotou; Niels Matthes; Marc Faber; Christoph-Thomas Germer; Ana Maria Waaga-Gasser; Martin Gasser
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

6.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

Review 7.  Novel anti-angiogenic compounds for application in tumor therapy - COP9 signalosome-associated kinases as possible targets.

Authors:  Chris Braumann; Judith Tangermann; Christoph A Jacobi; Joachim M Müller; Wolfgang Dubiel
Journal:  Mini Rev Med Chem       Date:  2008-05       Impact factor: 3.862

Review 8.  Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.

Authors:  P H Sugarbaker
Journal:  Int J Hyperthermia       Date:  2007-08       Impact factor: 3.914

9.  F-box-directed CRL complex assembly and regulation by the CSN and CAND1.

Authors:  Michael W Schmidt; Philip R McQuary; Susan Wee; Kay Hofmann; Dieter A Wolf
Journal:  Mol Cell       Date:  2009-09-11       Impact factor: 17.970

10.  CSN- and CAND1-dependent remodelling of the budding yeast SCF complex.

Authors:  Aleksandra Zemla; Yann Thomas; Sylwia Kedziora; Axel Knebel; Nicola T Wood; Gwenaël Rabut; Thimo Kurz
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  4 in total

Review 1.  Alkylating anticancer agents and their relations to microRNAs.

Authors:  Bernhard Biersack
Journal:  Cancer Drug Resist       Date:  2019-03-19

Review 2.  The Role of the COP9 Signalosome and Neddylation in DNA Damage Signaling and Repair.

Authors:  Dudley Chung; Graham Dellaire
Journal:  Biomolecules       Date:  2015-09-30

3.  Novel insights into biomarkers associated with renal cell carcinoma.

Authors:  Binghai Chen; Zhimin Jiao; Xifeng Yin; Zhounan Qian; Jie Gu; Hao Sun
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

4.  Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis.

Authors:  Maciej Nowacki; Marek Wisniewski; Karolina Werengowska-Ciecwierz; Katarzyna Roszek; Joanna Czarnecka; I Łakomska; Tomasz Kloskowski; Dominik Tyloch; Robert Debski; Katarzyna Pietkun; Marta Pokrywczynska; Dariusz Grzanka; Rafał Czajkowski; Gerard Drewa; A Jundziłł; Joseph K Agyin; Samy L Habib; Artur P Terzyk; Tomasz Drewa
Journal:  Oncotarget       Date:  2015-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.